Early stage support technologies

Infarnosys project: open for out-licensing and/or co-development partnership

SME Instrument Phase I winner project

Summary of invention:

Novel biomarker diagnostic system for the assessment of the prognosis of acute myocardial ischemia/reperfusion injury and infarction and the effectiveness of the treatment.

Scientific background:

For both men and women, coronary artery disease is the leading cause of death in Europe in spite of the fact that 80% of premature heart diseases are preventable. Earlier and better diagnosis of cardiac ischemia and reperfusion injury is crucial for reducing the number of deaths connected to cardiovascular diseases. Measuring MMP and nitrotyrosine levels enables predicting the occurrence of heart attack and helps to start the treatment much earlier. Our diagnostic marker combination has already been tested in several pre-clinical studies and in a pilot clinical study (Bencsik et al, Eur J Clin Invest, 2015).

Aims:

– novel biomarker diagnostic system for earlier and better diagnosis of cardiac ischemia/reperfusion injury
– prediction of the effectiveness of cardioprotective treatments
– automated zymography-based device for the detection of MMP-2 and MMP-9 activities as a Minimum Viable Product for research market entry

Advantages:

– market viability confirmed
– project is based on H2020 SME Instrument “Champion” project
– immediate and growing need in research market segment for automated gelatin zymography device
– Minimum Viable Product for research market entry replaces current laborious, skilful, and time-consuming lab work
– earlier and better diagnosis of cardiac ischemia/reperfusion injury as compared to currently available methods
– prediction of the effectiveness of cardioprotective treatments

Planned project duration:

24 months up to Minimum Viable Product

The project is open for co-development and/or investors. For further details contact us: businessdevelopment@pharmahungary.com.